Asset assessment
Decide whether to license an asset, and how: Sleuth maps the rivals it will launch against, works out who’s left to treat, benchmarks its data cohort by cohort, and forecasts sales.
Use it when
- You're in BD, corporate development, or at a fund, with an asset in front of you and a deal review coming.
- You need to check a partner's asking price against what the asset is likely to earn.
- You want a portfolio review or partnering story for an asset in your own pipeline.
What to have ready
The asset's name, the patients it's for, what its data shows so far, and the decision you face, such as licensing its U.S. rights. Pick the year you want the forecast for.
How it runs
- Describe the asset. The asset, its patients, its data, and the deal in question.
- Decide what counts. Choose how to score it: clinical differentiation, competitive room, patients still eligible, commercial size, and development maturity, and how much each one counts.
- Shape the plan. Sleuth shows its four steps: profile the asset and its rivals, map the standard of care in your forecast year, benchmark the data, and forecast and score. Change the forecast year before it runs.
- Get the analysis. A score and a recommendation, the forecast with every input laid out, and the landscape and benchmarks as datasets.
What you get
| Your question | What Sleuth gives you |
|---|---|
| Who will it launch against? | Every rival program in the indication, from Phase 1 to approved, counted once and ordered by stage, so you see where the asset would land in line. |
| Who's left to treat by launch? | The standard of care today and in your forecast year, with each trial, label, and guideline change dated, and the share of patients still eligible for the asset. |
| Does its data beat theirs? | Efficacy, durability, and safety compared cohort by cohort, with every comparison that isn't like for like flagged. |
| What's it worth, and what should we offer? | A sales forecast built input by input, the inputs that move it most, and a recommendation on whether and how to license. |
A finished example
Should you license enzomenib's U.S. rights? Sleuth says pursue, with conditions. Sumitomo Pharma's menin inhibitor in relapsed AML, set against every other menin inhibitor in the clinic. Time on drug moves its 2029 sales most. See the full example
Questions
Can we use our own assumptions?
Yes. Every forecast input is laid out with its source and range, so you can put in your own price, share, or time on therapy and see what changes.
What if the trials aren't comparable?
Sleuth flags each comparison that isn't like for like, such as pooled doses, a different patient mix, or a combination regimen, beside the number.
Does it include rivals from China?
Yes. They're in the competitive set and marked, as three of enzomenib's are. China coverage
How far out does the forecast go?
To the forecast year you choose. The example forecasts U.S. sales in 2029.
Does it say what to offer?
Yes. The recommendation turns the forecast into terms, such as how large the upfront should be and which conditions to set before exercising an option.
Can I run it on an asset from our own pipeline?
Yes. The same steps work on your own asset, for a partnering story or a portfolio review.
The plan shows the size of the job before anything runs: rows times analytical columns is the credits it will use. How credits work
Next questions on the same project
Asset scouting finds other assets to compare. Standard of care evolution goes deeper on the market the asset launches into. Graveyard analysis shows what ended drugs like it.
Updated November 9, 2026